Minerva Neurosciences, Inc. (NASDAQ:NERV) Q2 2019 Results Earnings Conference Call August 5, 2019 8:30 AM ET Company Participants William Boni - Vice President of Investor Relations and Corporate Communications Remy Luthringer - Chief Executive Officer Richard Russell - President Geoff Race - Executive Vice President, Chief Financial Officer and Chief Business Officer Conference Call Participants Joel Beatty - Citi Douglas Tsao - H.C. Wainwright Jason Butler - JMP Securities Biren Amin - Jefferies Operator ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36517 Minerva Neurosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 26-0784194 (State or Other Jurisdiction of In ...

Clinical Expertise and Patient Focus June, 2019 All trademarks, trade names and service marks appearing in this presentation are the property of their respective owners. 2 Forward-Looking Statement Safe-Harbor This presentation contains forward-looking statements about Minerva Neurosciences which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, reflect management's expectati ...

Minerva Neurosciences, Inc. (NASDAQ:NERV) Q1 2019 Results Conference Call May 6, 2019 8:30 AM ET Company Participants William Boni - Vice President of Investor Relations and Corporate Communications Remy Luthringer - Executive Chairman and Chief Executive Officer Rick Russell - President Geoff Race - Executive Vice President, Chief Financial Officer and Chief Business Officer Conference Call Participants Roy Buchanan - JMP Securities Joel Beatty - Citigroup Operator Welcome to the Minerva Neurosciences Firs ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36517 Minerva Neurosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 26-0784194 (State or Other Jurisdiction of I ...

Minerva Neurosciences, Inc. (NASDAQ:NERV) Q4 2018 Earnings Conference Call March 12, 2019 8:30 AM ET Company Participants William Boni - Vice President of Investor Relations & Corporate Communications Remy Luthringer - Executive Chairman & Chief Executive Officer Rick Russell - President Geoff Race - Executive Vice President, Chief Financial Officer & Chief Business Officer Conference Call Participants Jason Butler - JMP Securities Joel Beatty - Citi Biren Amin - Jefferies Operator Welcome to the Minerva Ne ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36517 Minerva Neurosciences, Inc. (Exact name of Registrant as specified in its Charter) Delaware 26-0784194 (State or other jurisdic ...